Lipoprotein (a): a historical appraisal
- PMID: 27821413
- PMCID: PMC5234731
- DOI: 10.1194/jlr.R071571
Lipoprotein (a): a historical appraisal
Abstract
Initially, lipoprotein (a) [Lp(a)] was believed to be a genetic variant of lipoprotein (Lp)-B. Because its lipid moiety is almost identical to LDL, Lp(a) has been deliberately considered to be highly atherogenic. Lp(a) was detected in 1963 by Kare Berg, and individuals who were positive for this factor were called Lpa+ Lpa+ individuals were found more frequently in patients with coronary heart disease than in controls. After the introduction of quantitative methods for monitoring of Lp(a), it became apparent that Lp(a), in fact, is present in all individuals, yet to a greatly variable extent. The genetics of Lp(a) had been a mystery for a long time until Gerd Utermann discovered that apo(a) is expressed by a variety of alleles, giving rise to a unique size heterogeneity. This size heterogeneity, as well as countless mutations, is responsible for the great variability in plasma Lp(a) concentrations. Initially, we proposed to evaluate the risk of myocardial infarction at a cut-off for Lp(a) of 30-50 mg/dl, a value that still is adopted in numerous epidemiological studies. Due to new therapies that lower Lp(a) levels, there is renewed interest and still rising research activity in Lp(a). Despite all these activities, numerous gaps exist in our knowledge, especially as far as the function and metabolism of this fascinating Lp are concerned.
Keywords: atherosclerosis; metabolism; myocardial infarction; review.
Copyright © 2017 by the American Society for Biochemistry and Molecular Biology, Inc.
Figures
![Fig. 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5234731/bin/1fig1.gif)
![Fig. 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5234731/bin/1fig2.gif)
![Fig. 3.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5234731/bin/1fig3.gif)
![Fig. 4.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5234731/bin/1fig4.gif)
![Fig. 5.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5234731/bin/1fig5.gif)
![Fig. 6.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5234731/bin/1fig6.gif)
Similar articles
-
Lipoprotein(a): genotype-phenotype relationship and impact on atherogenic risk.Metab Syndr Relat Disord. 2011 Dec;9(6):411-8. doi: 10.1089/met.2011.0026. Epub 2011 Jul 12. Metab Syndr Relat Disord. 2011. PMID: 21749171 Free PMC article. Review.
-
Sequence polymorphisms in the apolipoprotein(a) gene and their association with lipoprotein(a) levels and myocardial infarction. The ECTIM Study.Atherosclerosis. 1999 Jun;144(2):323-33. doi: 10.1016/s0021-9150(98)00333-5. Atherosclerosis. 1999. PMID: 10407493
-
Genetics and metabolism of lipoprotein(a) and their clinical implications (Part 1).Wien Klin Wochenschr. 1999 Jan 15;111(1):5-20. Wien Klin Wochenschr. 1999. PMID: 10067265 Review.
-
Lipoprotein(a) as a risk factor for coronary artery disease.Am J Cardiol. 1998 Dec 17;82(12A):57U-66U; discussion 86U. doi: 10.1016/s0002-9149(98)00954-0. Am J Cardiol. 1998. PMID: 9915664 Review.
-
High lipoprotein(a) in children from kindreds with parental premature myocardial infarction.Pediatr Res. 1993 Nov;34(5):670-4. doi: 10.1203/00006450-199311000-00021. Pediatr Res. 1993. PMID: 8284108
Cited by
-
Comparative Analysis of Atherogenic Lipoproteins L5 and Lp(a) in Atherosclerotic Cardiovascular Disease.Curr Atheroscler Rep. 2024 Jul;26(7):317-329. doi: 10.1007/s11883-024-01209-3. Epub 2024 May 16. Curr Atheroscler Rep. 2024. PMID: 38753254 Free PMC article. Review.
-
Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?Int J Mol Sci. 2024 Mar 21;25(6):3537. doi: 10.3390/ijms25063537. Int J Mol Sci. 2024. PMID: 38542510 Free PMC article. Review.
-
Exploring PCSK9 Genetic Impact on Lipoprotein(a) via Dual Approaches: Association and Mendelian Randomization.Int J Mol Sci. 2023 Sep 28;24(19):14668. doi: 10.3390/ijms241914668. Int J Mol Sci. 2023. PMID: 37834124 Free PMC article.
-
Lipoprotein(a): Just an Innocent Bystander in Arterial Hypertension?Int J Mol Sci. 2023 Aug 29;24(17):13363. doi: 10.3390/ijms241713363. Int J Mol Sci. 2023. PMID: 37686169 Free PMC article. Review.
-
Pharmacoeconomic analysis (CER) of Dulaglutide and Liraglutide in the treatment of patients with type 2 diabetes.Front Endocrinol (Lausanne). 2023 Jan 23;14:1054946. doi: 10.3389/fendo.2023.1054946. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 36755915 Free PMC article. Clinical Trial.
References
-
- Scanu A. M. 1990. Lipoprotein (a). Academic Press, San Diego.
-
- Nordestgaard B. G., Chapman M. J., and Ginsberg H. N.. 2013. Lipoprotein(a): A Handbook for Clinicians. Available at: https://itunes.apple.com/gb/app/lipoprotein-atherosclerosis/id648424814?....
-
- Utermann G. 1989. The mysteries of lipoprotein (a). Science. 246: 904–910. - PubMed
-
- Barnathan E. S. 1993. Has lipoprotein ‘little’ (a) shrunk? JAMA. 270: 2224–2225. - PubMed
-
- Kostner K. M., and Kostner G. M.. 2002. Lipoprotein(a): still an enigma? Curr. Opin. Lipidol. 13: 391–396. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous